FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, a…
Uncategorized
RIBOMIC annonce les premiers résultats positifs de l'essai clinique de phase 1/2a du RBM-007 (étude SUSHI) chez des patients atteints de dégénérescence maculaire liée à l'âge humide
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., société pharmaceutique de stade clinique spécialisée dans les produits thérapeutiques à aptamères et cotée sur le Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui les premiers résultats positifs issus de l’étude SUSHI, étude clinique à dose ascendante unique de Phase 1/2a du RBM-007, aptamère anti-FGF2, chez neuf patients atteints de dégénérescence maculaire liée à l’âge humide (DMLA humide). L’étude SUSHI a atteint le cr
RIBOMIC gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., ein auf Aptamer-Therapeutika im klinischen Stadium spezialisiertes Pharmaunternehmen, das am Mothers-Markt der Tokioter Börse gehandelt wird (Börsenkürzel: 4591), gab heute positive Topline-Ergebnisse seiner SUSHI…
Study provides new insight into the heritability of coronary artery disease
A collaboration involving the Icahn School of Medicine at Mount Sinai, the German Heart Center Munich, AstraZeneca, and Karolinska Institutet in Sweden has demonstrated that more than 30 percent of heart disease risk stems from genetic factors, much mo…
Uncategorized
LipiFlow more effective than warm compress for dry eye disease
One session of vectored thermal pulsation was more efficacious than a warm compress for treating dry eye disease, according to a study.The systematic review and meta-analysis consisted of 385 patients from four randomized controlled trials that compare…
Uncategorized
Glaucoma Market Spotlight 2019: 10-Year Disease Prevalence Forecast, Licensing and Acquisition Deals, Revenue Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Glaucoma” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts Key Takeaways The author estimates that in 2017, there were 95.5 million prevalen